1h Free Analyst Time
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.Speak directly to the analyst to clarify any post sales queries you may have.
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 8 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II stages are 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Ophthalmology, Cardiovascular, Central Nervous System, Dermatology, Immunology, Infectious Disease, Musculoskeletal Disorders and Respiratory which include indications Melanoma, Wet (Neovascular/Exudative) Macular Degeneration, Achondroplasia, Bone Disorders, Cancer Pain, Choroidal Neovascularization, Coronavirus Disease 2019 (COVID-19), Critical Limb Ischemia, Dengue Fever, Diabetic Foot Ulcers, Diabetic Macular Edema, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Intermittent Claudication, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Non-Proliferative Diabetic Retinopathy (NPDR), Non-Small Cell Lung Cancer, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Peripheral Artery Occlusive Disease (PAOD), Pressure Ulcers, Rheumatoid Arthritis, Solid Tumor and Venous Leg Ulcers (Crural Ulcer).
The latest report Fibroblast Growth Factor 2 - Drugs In Development, 2022, outlays comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
- The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview
- Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development
- Aurealis Therapeutics AG
- ID Pharma Co Ltd
- RemeGen Co Ltd
- Ribomic Inc
- Zucero Therapeutics Ltd
- Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles
- AUP-16 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DVC-10101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- pixatimod - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RBM-007 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RC-28 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TR-764 - Drug Profile
- Product Description
- Mechanism Of Action
- Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products
- Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products
- Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones
- Featured News & Press Releases
- Apr 19, 2022: RIBOMIC announces completion of IND submission for an observational study for continuous phase 2 trial of RBM-007 for treatment of Achondroplasia
- Mar 23, 2022: RIBOMIC provides update on RBM-007 program in wet age-related macular degeneration
- Dec 28, 2021: RIBOMIC announces preliminary topline data from phase 2 trials of RBM-007 for wet age-related macular degeneration
- Nov 15, 2021: RIBOMIC announces RBM-007 phase 1 clinical trial results for achondroplasia
- Sep 30, 2021: RIBOMIC announces presentation of masked preliminary interim data from phase 2 trials of RBM-007 for wet age-related macular degeneration at the Retina Society 2021 Meeting
- Aug 30, 2021: RIBOMIC completes patient enrollment of its US phase 2 open-label extension clinical trial of RBM-007 for wet age-related macular degeneration (RAMEN Study)
- Aug 05, 2021: RIBOMIC completes patient enrollment of its US phase 2 clinical trial of RBM-007 for wet age-related macular degeneration (TOFU Study)
- Jul 12, 2021: RIBOMIC announces first patient dosed in an investigator sponsored trial of RBM007 in treatment naïve wet AMD patients
- May 12, 2021: RIBOMIC announces completion of its phase I trial of RBM-007 for the treatment of achondroplasia
- May 06, 2021: RIBOMIC announces publication of research paper on aptamer drug discovery for achondroplasia
- Feb 01, 2021: Ribomic announces completion of 50% of enrollment of its phase 2 clinical trial for wet age-related macular degeneration (TOFU study)
- Nov 11, 2020: RIBOMIC announces initiation of RAMEN open-label extension clinical trial for RBM007 in wet AMD patients
- Jul 15, 2020: RIBOMIC announces dosing of first subject in RBM-007 phase 1 clinical trial for Achondroplasia
- May 11, 2020: Safe-to-proceed under IND to initiate clinical trials of RBM-007 for treatment of achondroplasia
- May 07, 2020: RIBOMIC resumes trial recruitment suspended by coronavirus
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Aurealis Therapeutics AG, 2022
- Pipeline by ID Pharma Co Ltd, 2022
- Pipeline by RemeGen Co Ltd, 2022
- Pipeline by Ribomic Inc, 2022
- Pipeline by Zucero Therapeutics Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurealis Therapeutics AG
- ID Pharma Co Ltd
- RemeGen Co Ltd
- Ribomic Inc
- Zucero Therapeutics Ltd
